论文部分内容阅读
目的报道新发现的4例 cCD79a/cCD22异常表达的t(8;21)急性髓系白血病(AML)。方法分析4例患者的细胞形态学、免疫学、细胞遗传学、分子生物学(MICM)分型及临床特征。结果伴 cCD79a/cCD22表达的t(8;21)(q22;q22)的 AML 特点:①无显著的性别差异;②发病年龄较轻;③可有髓外浸润;④外周血白细胞计数不增高;⑤骨髓细胞形态学显示为粒细胞白血病,且原始细胞显著增多;⑥免疫表型均为 B 淋巴系和髓系共表达,CD34表达阳性,且为高表达;⑦染色体改变除t(8;21)(q22:q22)外,亦常见性染包体缺失及复杂染色体改变;⑧AML1/ETO 融合基因检测均阳性;⑨对兼顾髓系和淋巴系的联合治疗方案反应较好。结论 t(8;21)AML 患者易伴有 B 细胞表型共表达
Objective To report the newly discovered t (8; 21) acute myeloid leukemia (AML) in 4 newly diagnosed cases of cCD79a / cCD22. Methods The morphology, immunology, cytogenetics, molecular biology (MICM) typing and clinical features of 4 patients were analyzed. Results The AML characteristics of t (8; 21) (q22; q22) with cCD79a / cCD22 expression were as follows: ① There was no significant gender difference; ② The age of onset was mild; ③ The extramedullary infiltration was observed; ④ The peripheral blood leukocyte count did not increase; ⑤The morphology of myeloid cells showed myeloid leukemia and the number of primitive cells increased significantly. ⑥The immunophenotypes were both B lymphoid and myeloid co-expression, with positive expression of CD34 and high expression; ⑦ Chromosome changes except t (8; 21 ) (q22: q22), but also the lack of sex chromosomes and complex chromosome changes; ⑧ AML1 / ETO fusion gene test were positive; ⑨ pairs of both myeloid and lymphatic system combination therapy response better. Conclusions t (8; 21) AML patients are easily associated with B cell phenotypes